Targets › MGAT5
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jul 2027.
Catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides. Catalyzes an important step in the biosynthesis of branched, complex-type N-glycans, such as those found on EGFR, TGFR (TGF-beta receptor) and CDH2. (UniProt, Q09328)
Open in Phaseline: the race on MGAT5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Phost'In Therapeutics | PhOx430 Acetylglucosaminyltransferase V inhibitor | MGAT5 | Phase 1 | Malignant Tumor | Jul 2027 |
Malignant Tumor (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.